PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1507299
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1507299
US Esoteric Testing Market is valued approximately USD 6.87 Billion in 2023 and is anticipated to grow with a healthy growth rate of more than 11.67% over the forecast period 2024-2032. Esoteric tests are specialist laboratory methods that are usually available in standard clinical laboratories because of their complexity, the rarity of the conditions they diagnose, or the specialist knowledge needed to interpret the results. These tests, which are carried out in specialist facilities, include genetic testing for unusual diseases, diagnostics for rare infections, and sophisticated biomarker assays. Esoteric diagnostics, in contrast to standard blood or urine testing, are typically contracted out to reference labs that possess the requisite equipment and expertise. These diagnostics, which make use of cutting-edge technologies like real-time polymerase chain reaction and next-generation sequencing, are crucial in some therapeutic situations and scientific studies. The rise in technological advancements is a key trend for the US Esoteric Testing Market. Continuous innovations in molecular diagnostics, next-generation sequencing, and advanced imaging techniques are expanding the capabilities and accuracy of esoteric testing, leading to increased adoption.
US is poised to lead the esoteric testing market due to rising research and development initiatives, increased investments, growing burdens of chronic diseases, and a growing prevalence of rare diseases. According to data from NORD, approximately 25-30 million individuals were affected by a rare disease in 2021, with nearly one in ten Americans having a rare disease, and over half of these cases involving children. Additionally, data from the NIH RCDC reveals that funding for rare disease research in the United States was estimated at USD 6,191 million in 2021, projected to reach USD 6,482 million by the end of 2022. This substantial investment, coupled with the rising prevalence of rare diseases, is anticipated to drive increased demand for esoteric testing, consequently fostering market expansion in this area. Also, robust healthcare infrastructure, substantial buying potential, and a surge in esoteric testing adoption rates are further attributing to the demand of the esoteric testing across the globe. Furthermore, the market's growth is further fueled by the introduction of new testing services and strategic collaborations among major players in the region. For instance, in January 2021, BioReference Laboratories, Inc., a subsidiary of OPKO Health, unveiled Scarlet Health, an integrated digital platform offering on-demand diagnostic services from the comfort of one's home. Scarlet's design mirrors familiar consumer tools, ensuring user-friendly accessibility and convenience. Similarly, in February 2021, GRAIL, Inc. partnered with Quest Diagnostics to provide phlebotomy services supporting Galleri, GRAIL's multi-cancer early detection blood test. However, stringent regulatory framework, coupled with the lack of skilled healthcare professional in developing countries is expected to stifle US Esoteric Testing Market growth between 2024 and 2032.